Recursion Pharmaceuticals/RXRX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1YMAX

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage TechBio company decoding biology to industrialize drug discovery. Its Recursion Operating System (OS), a platform built across diverse technologies, enables the Company to map and navigate trillions of biological and chemical relationships within the Recursion Data Universe. The Company integrates physical and digital components as iterative loops of atoms and bits scaling wet lab biology and chemistry data organized into virtuous cycles with computational tools to rapidly translate in silico hypotheses into validated insights and novel chemistry. Its clinical programs include REC-994, REC-2282, REC-4881 and REC-3964. REC-994 is an orally bioavailable, superoxide scavenger small molecule being development for the treatment of symptomatic cerebral cavernous malformation (CCM). REC-2282 for the potential treatment of neurofibromatosis type 2. REC-3964 for the prevention of recurrent Clostridioides difficile infection.

Ticker

RXRX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Christopher Gibson

Employees

500

Headquarters

Salt lake city, United States

RXRX Metrics

BasicAdvanced
$2B
Market cap
-
P/E ratio
-$1.62
EPS
-
Beta
-
Dividend rate
$2B
$16.75
$4.97
5.3M
4.648
0.267
0.281
-59.76%
-85.19%
-69.49%
42.562
4.902
6.227
-0.88%
-17.33%
124.07%

What the Analysts think about RXRX

Analyst Ratings

Majority rating from 7 analysts.
Hold

RXRX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-666.42% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$14M
26.85%
Net income
-$91M
-1.72%
Profit margin
-666.42%
-22.53%

RXRX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 7.87%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.38
-$0.43
-$0.42
-$0.39
-
Expected
-$0.37
-$0.39
-$0.45
-$0.42
-$0.41
Surprise
1.53%
11.69%
-6.41%
-7.87%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
Market closedNon-fractional

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Recursion Pharmaceuticals stock?

Recursion Pharmaceuticals (RXRX) has a market cap of $2B as of June 19, 2024.

What is the P/E ratio for Recursion Pharmaceuticals stock?

The price to earnings (P/E) ratio for Recursion Pharmaceuticals (RXRX) stock is 0 as of June 19, 2024.

Does Recursion Pharmaceuticals stock pay dividends?

No, Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders as of June 19, 2024.

When is the next Recursion Pharmaceuticals dividend payment date?

Recursion Pharmaceuticals (RXRX) stock does not pay dividends to its shareholders.

What is the beta indicator for Recursion Pharmaceuticals?

Recursion Pharmaceuticals (RXRX) does not currently have a Beta indicator.

What is the Recursion Pharmaceuticals stock price target?

The target price for Recursion Pharmaceuticals (RXRX) stock is $13, which is NaN% below the current price of $. This is an average based on projections from 6 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Recursion Pharmaceuticals stock

Buy or sell Recursion Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing